Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
49.23
+0.26 (0.53%)
At close: Aug 13, 2025, 4:00 PM
48.96
-0.27 (-0.55%)
Pre-market: Aug 14, 2025, 9:01 AM EDT
Qiagen Employees
Qiagen had 5,967 employees as of December 31, 2023. The number of employees decreased by 211 or -3.42% compared to the previous year.
Employees
5,967
Change (1Y)
-211
Growth (1Y)
-3.42%
Revenue / Employee
$341,892
Profits / Employee
$62,575
Market Cap
10.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,967 | -211 | -3.42% |
Dec 31, 2022 | 6,178 | 150 | 2.49% |
Dec 31, 2021 | 6,028 | 418 | 7.45% |
Dec 31, 2020 | 5,610 | 514 | 10.09% |
Dec 31, 2019 | 5,096 | 144 | 2.91% |
Dec 31, 2018 | 4,952 | 264 | 5.63% |
Dec 31, 2017 | 4,688 | 4 | 0.09% |
Dec 31, 2016 | 4,684 | 125 | 2.74% |
Dec 31, 2015 | 4,559 | 220 | 5.07% |
Dec 31, 2014 | 4,339 | 324 | 8.07% |
Dec 31, 2013 | 4,015 | 16 | 0.40% |
Dec 31, 2012 | 3,999 | 61 | 1.55% |
Dec 31, 2011 | 3,938 | 351 | 9.79% |
Dec 31, 2010 | 3,587 | 92 | 2.63% |
Dec 31, 2009 | 3,495 | 454 | 14.93% |
Dec 31, 2008 | 3,041 | 379 | 14.24% |
Dec 31, 2007 | 2,662 | 708 | 36.23% |
Dec 31, 2006 | 1,954 | 365 | 22.97% |
Dec 31, 2005 | 1,589 | 267 | 20.20% |
Dec 31, 2004 | 1,322 | -231 | -14.87% |
Dec 31, 2003 | 1,553 | -98 | -5.94% |
Dec 31, 2002 | 1,651 | 94 | 6.04% |
Dec 31, 2001 | 1,557 | 242 | 18.40% |
Dec 31, 2000 | 1,315 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
QGEN News
- 7 days ago - Qiagen N.V. (QGEN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability - Business Wire
- 22 days ago - QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels - Business Wire
- 5 weeks ago - QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast - Business Wire
- 6 weeks ago - QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board - Business Wire
- 2 months ago - Qiagen and Gencurix Enter Clinical Diagnostics Partnership - Market Watch
- 2 months ago - QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership - Business Wire
- 2 months ago - QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs) - Business Wire